Drug Trial Radar · NCT04348136
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Actual
Start
Sep 1, 2019
Primary completion
Mar 31, 2030
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Conditions
- Mucopolysaccharidosis II
Interventions
JR-141Drug
IV infusion, 2.0 mg/kg/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse eventsTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
- Occurrence of adverse reactionsTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
- Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Incidence of abnormal vital signsTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Laboratory tests (urinalysis)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Vital signs (pulse rate)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Vital signs (body temperature)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Vital signs (blood pressure)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- 12-lead electrocardiogramTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Antibody tests (anti-JR-141 antibodies)Time frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- IARTime frame: From the start of study (Week 52 of preceding study) up to the end of study, up to approximately 10.6 years
- Time course of developmental assessment data (Kyoto Scale of Psychological Development 2001) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of developmental assessment data (Vineland-II) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of developmental assessment data (Bayley-III or KABC-II) from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of CSF substrate (HS and DS) concentrations from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of serum HS and DS concentrations from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of urinary HS concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of urinary DS concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of uronic acid concentration from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of liver volume (assessed by CT or MRI) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of spleen volume (assessed by CT or MRI) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of cardiac function (assessed by echocardiography) from initial dosing in the preceding studyTime frame: Week 78, 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of 6-minute walk test distance from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
- Time course of joint range of motion from initial dosing in the preceding studyTime frame: Week 104, an average of 52 weeks after Week 104, up to approximately 10.6 years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Fukui Clinical site
Fukui, Japan
Fukuoka Clinical site 2
Fukuoka, Japan
Fukuoka Clinical site
Fukuoka, Japan
Gifu Clinical site
Gifu, Japan
Hiroshima Prefectural Hospital
Hiroshima, Japan
Hokkaido Clinical site
Hokkaido, Japan
Kananagawa Ckinical site
Kanagawa, Japan
Kumamoto Clinical site
Kumamoto, Japan
Okayama Clinical site
Okayama, Japan
Okayama Clinical site 2
Okayama, Japan
Okinawa Clinical site
Okinawa, Japan
Osaka Clinical site 3
Osaka, Japan
Osaka Clinical site 2
Osaka, Japan
Osaka Clinical site
Osaka, Japan
Saitama Clinical site
Saitama, Japan
Shizuoka Clinical site
Shizuoka, Japan
Shizuoka Clinical site 2
Shizuoka, Japan
Tochigi Clinical site
Tochigi, Japan
Tokyo Clinical site
Tokyo, Japan
Tottori Clinical site
Tottori, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.